CIK 0001006281
- Non-accelerated filer
- Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 650643773
- Phone
- +1 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2008-02-25 | Yossi Maimon VP, Chief Financial Officer | Sale | −33,300 | $3.18 | $106K | 26,700 |
| 2008-02-22 | Yossi Maimon VP, Chief Financial Officer | Option exercise | +86,176 | $0.97 | $84K | 86,176 |
| 2008-02-22 | Yossi Maimon VP, Chief Financial Officer | Shares withheld for taxes | −26,176 | $3.20 | $84K | 60,000 |
| 2008-02-22 | Yossi Maimon VP, Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −86,176 | 533,796 | ||
| 2008-02-07 | Yossi Maimon VP, Chief Financial Officer | Grant or award · Stock Options (Right to Buy) | +175,000 | 175,000 | ||
| 2006-12-31 | Yossi Maimon VP, Chief Financial Officer | Grant or award · Stock Options (Right to Buy) | +619,972 | 619,972 |
Page 1 of 1 · 6 trades